A Guide for Adult Nephrologists and Hematologists to Managing Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy in Teens Transitioning to Young Adults

Adv Chronic Kidney Dis. 2022 May;29(3):231-242. doi: 10.1053/j.ackd.2022.04.003.

Abstract

Atypical hemolytic uremic syndrome and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis are ultra-rare chronic, complement-mediated diseases with childhood manifestation in a majority of cases. Transition of clinical care of patients from pediatric to adult nephrologists-typically with controlled disease in native or transplant kidneys in case of atypical hemolytic uremic syndrome and often with chronic progressive disease despite treatment efforts in case of C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis-identifies a challenging juncture in the journey of these patients. Raising awareness for the vulnerability of this patient cohort; providing education on disease pathophysiology and management including the use of new, high-precision complement antagonists; and establishing an ongoing dialog of patients, families, and all members of the health care team involved on either side of the age divide will be inevitable to ensure optimal patient outcomes and a safe transition of these patients to adulthood.

Keywords: Atypical hemolytic uremic syndrome; C3 glomerulopathy; Education; Transition; Transplantation.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Antigen-Antibody Complex / therapeutic use
  • Atypical Hemolytic Uremic Syndrome* / diagnosis
  • Atypical Hemolytic Uremic Syndrome* / therapy
  • Child
  • Complement System Proteins
  • Glomerulonephritis, Membranoproliferative* / therapy
  • Humans
  • Kidney Diseases*
  • Nephrologists
  • Young Adult

Substances

  • Antigen-Antibody Complex
  • Complement System Proteins